Results 121 to 130 of about 84,453 (255)
Abstract Hadrosaurid dinosaurs are generally regarded as “crested” or “non‐crested” depending on the presence or absence of a bony cranial crest. At least one supposedly “non‐crested” hadrosaur is known to have possessed a soft tissue cranial crest (or comb), based on an exceptionally preserved “mummified” specimen. Here we redescribe this specimen and
Henry S. Sharpe +4 more
wiley +1 more source
A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis
Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane +33 more
wiley +1 more source
Differences in Hospitalization and Inpatient Death Patterns by Incarceration Status in 31 US Jurisdictions, 2021. [PDF]
Kennedy BS, Richeson RP, Houde AJ.
europepmc +1 more source
A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen +14 more
wiley +1 more source
Burden of Pseudoexfoliation and Pigmentary Glaucoma among American Indian or Alaska Native Patients. [PDF]
Cohen SA +4 more
europepmc +1 more source
Seasonal Drivers of Density in a Subarctic Population of Northern Red-Backed Voles. [PDF]
Swanson S +5 more
europepmc +1 more source
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi +12 more
wiley +1 more source
Understanding Risk Factors for Otitis Media in Rural Alaska Native Children: A Cohort Study. [PDF]
Patterson RH +6 more
europepmc +1 more source

